6 unknown. 6 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 6 |
| Phase 3 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Craniofacial Abnormalities: new trials by email Literature Review of Craniofacial Abnormalities trials Research Report on Craniofacial Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer BR790+anlotinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Shanghai Gopherwood Biotech Co., Ltd. | 90 | 2023-02-01 | 2023-02-10 |
| Pharmacological Treatment on the Recovery of Neurosensory Disturbance After Bilateral Sagittal Split Osteotomy Orthognathic Surgery, Melatonin 10 MG Oral Tablet, Hydroxycobalamin - Retrognathism, Prognathism | Phase 2 / Phase 3 | Unknown | Universitat Internacional de Catalunya | 220 | 2022-09-30 | 2022-09-13 |
| Dexmedetomidine Versus Sevoflurane in Children With Anticipated Difficult Intubation dexmedetomidine, sevoflurane - Craniofacial Abnormalities, Mandibular Hypoplasia | Phase 2 | Unknown | Alexandria University | 40 | 2020-06-01 | 2020-06-12 |
| Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations Infigratinib - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Unknown | LianBio LLC | 80 | 2020-05-13 | 2022-06-27 |
| Effects of Oral Melatonin on Neurosensory Recovery Following Facial Osteotomies Oral Melatonin 10mg, Placebo - Dentofacial Deformities | Phase 2 | Unknown | The University of Hong Kong | 40 | 2016-06-01 | 2016-09-07 |
| Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome. omega-3 PUFAs, Standard care, placebo - 22q11 Deletion Syndrome | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 80 | 2014-06-01 | 2014-02-25 |
22q11 Deletion Syndrome (1) · Acrocephalosyndactylia (1) · Carcinoma, Non-Small-Cell Lung (1) · Dentofacial Deformities (1) · Micrognathism (1) · Noonan Syndrome (1) · Prognathism (1) · Psychotic Disorders (1) · Retrognathia (1) · Sensation Disorders (1) · Stomach Neoplasms (1)
Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Musculoskeletal Abnormalities (6) · Musculoskeletal Diseases (6) · Maxillofacial Abnormalities (3) · Stomatognathic Diseases (3) · Stomatognathic System Abnormalities (3) · Cardiovascular Abnormalities (2) · Cardiovascular Diseases (2) · Heart Defects, Congenital (2) · Heart Diseases (2) · Jaw Abnormalities (2) · Jaw Diseases (2) · Neoplasms (2)
Melatonin (2) · Cytidine (1) · Dexmedetomidine (1) · Fish Oils (1) · Hydroxocobalamin (1) · Orthognathic Surgery (1) · Sevoflurane (1) · Standard of Care (1) · Tablets (1) · Uridine (1) · infigratinib (1)
Alexandria University (1) · Bambino Gesù Hospital and Research Institute (1) · LianBio LLC (1) · Shanghai Gopherwood Biotech Co., Ltd. (1) · The University of Hong Kong (1) · Universitat Internacional de Catalunya (1)
China (1) · Egypt (1) · Holy See (1) · Hong Kong (1)
Baohui Han (1) · Crystal TY Lee, BDS (HKU) (1) · Marco Armando, MD, PhD (1) · Pedro Sole, DMD, OMFS (1) · Qiao Sun, Doctor (1) · Rehab A. Abd Elaziz, Ass.Prof. (1)